

BRICS Health Sector: Economic Shifts, Market Trends, and Innovation Frontiers

Global Health · Answer Key · 15 Questions

1. In 2025, which BRICS nation's pharmaceutical market was projected to reach USD 24.10 billion by 2033, exhibiting a significant CAGR of 7.66% driven by increasing healthcare consciousness and demand for novel therapies?

- A) India
- B) South Africa**
- C) Russia
- D) Brazil

2. Which BRICS country has seen its biotech stock surge by approximately 80% in a recent year, significantly outperforming its US counterpart and signaling a "genuine policy shift" to support innovative drug development?

- A) Brazil
- B) South Africa
- C) India
- D) China**

3. As of a 2025 report, the Russian pharmaceutical market was estimated to be worth around RUB 3.3 trillion, with domestic manufacturers supplying a dominant share of packaged drugs. What percentage of all packaged drugs in the state hospital segment (LPU) were Russian-made?

- A) 87.3%**
- B) 69.3%
- C) 51.2%
- D) 75.0%

4. India's pharmaceutical industry, a global giant, ranks third in volume and fourteenth in value worldwide. What percentage of global vaccine production does India account for, making it the largest producer?

- A) 20%
- B) 40%
- C) 60%**
- D) 80%

5. In South Africa's pharmaceutical market, the biopharmaceuticals sector, including biologics and biosimilars, is forecast to double to USD 2.85 billion by 2032, growing at a CAGR of 12.3%. What regulatory milestone, achieved by the South African Health Products Regulatory Authority (SAHPRA) in 2025, aligns local standards with the FDA and EMA?

A) ISO Certification

B) Membership in the International Council for Harmonisation (ICH)

C) World Health Organization (WHO) Prequalification

D) European Medicines Agency (EMA) Mutual Recognition Agreement

6. Brazil's Unified Health System (SUS) is set to see a budget allocation increase of 6.2% in 2025 compared to 2024. While primary and specialized care services are expected to benefit, which area is projected to have a decreased allocation?

A) Maternal Health

B) Indigenous Health

C) Cardiovascular Care

D) Oncology Services

7. A recent analysis indicates that China's biotech sector's long-term potential is underpinned by several factors. Which of the following is NOT consistently cited as a key advantage for Chinese biotechs in recent reports?

A) Lower costs

B) Faster development timelines

C) Larger domestic venture capital investment than the US

D) Increasingly translatable clinical data

8. The BRICS health agenda, particularly under India's 2026 presidency, has proposed several initiatives. Which of these was a key proposal aimed at addressing risk factors like unhealthy diets and physical inactivity to reduce non-communicable diseases?

A) BRICS Network of National Public Health Institutes

B) BRICS Mission for Healthy Lifestyles

C) Integrated Early Warning System for Infectious Diseases

D) Digital Health Architecture Initiative

9. In the Russian pharmaceutical market, the "Pharma 2030 Strategy" aims to increase the share of Russian-made drugs. While some versions cite a goal of 70% in value, another version of the plan suggests a more modest target. What is this more modest target for the domestic share in monetary terms by 2030?

- A) 55%
- B) 60%
- C) 43%**
- D) 50%

10. In 2025, Chinese biotechs reportedly notched a record amount in out-licensing agreements, with overseas pharmaceutical companies bolstering their pipelines. What was this record amount?

- A) \$138 billion**
- B) \$36.9 billion
- C) \$12.75 billion
- D) \$2.5 billion

11. South Africa's pharmaceutical market is expected to grow steadily, with a significant trend towards biologics and specialty drugs. In September 2025, Aspen received regulatory approval for a specific injector pen. Which therapy, significant for diabetes and obesity care, was approved?

- A) Wegovy
- B) Ozempic
- C) Mounjaro**
- D) Saxenda

12. Brazil's Ministry of Health announced a significant investment for the digitalization of its public basic healthcare system (SUS). What was the announced investment amount for 2023?

- A) US\$ 20 million
- B) US\$ 50 million
- C) US\$ 100 million
- D) US\$ 200 million**

13. India is a global leader in vaccine production. What percentage of global vaccine production does India contribute?

- A) 30%
- B) 45%
- C) 60%**
- D) 75%

14. The BRICS countries are increasingly collaborating on health. During the 15th BRICS Ministers of Health Meeting in Brasilia, Brazil, in June 2025, several areas of cooperation were discussed. Which of the following was NOT among the key areas called for by the PAHO Director for joint efforts?

- A) Strengthening local and regional production of medicines
- B) Accelerating health equity through disease elimination
- C) Advancing voluntary regulatory convergence
- D) Reducing domestic R&D investment in favor of imported technologies**

15. In Russia's pharmaceutical market, the "Pharma 2030 Strategy" aims to bolster domestic production. What is the estimated investment required to develop advanced therapy drugs and localize significant ingredients by 2030, as mentioned in a downside scenario projection?

- A) RUB 50 billion
- B) RUB 175 to 225 billion**
- C) RUB 80 billion
- D) RUB 3.9 trillion